^
Association details:
| Biomarker: | THBS2-L |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Cyramza (ramucirumab) (VEGFR-2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical development and evaluation of plasma angiogenesis factors from phase II study of FOLFIRI plus ramucirumab with recurrent colorectal cancer refractory to adjuvant chemotherapy with oxaliplatin/fluoropyrimidine (RAINCLOUD): RAINCLOUD-TR.
Published date:
01/17/2023
Excerpt:
Plasma sample collections were done at time points of pre-/ post-treatments in pts receiving FOLFIRI+Ram...low TSP-2 were better ORR (low vs high: 66.7%/20.0% (p=0.004, HR 7.54) and PFS 7.5M/4.3M (p=0.022, HR 0.45).
Secondary therapy:
FOLFIRI
DOI:
10.1200/JCO.2023.41.3_suppl.173
